This technology is a heterocyclic compound library platform designed for CNS drug discovery targeting neuroinflammation-driven disease mechanisms.
Oxazole- and oxadiazole-based compounds modulate NLRP3 inflammasome activation, suppressing IL-1β release and microglial activation.
The platform demonstrates antidepressant-like efficacy in inflammatory depression models where SSRIs show limited effectiveness.
By enabling subtype-specific and mechanism-driven development, it provides a differentiated alternative to monoaminergic CNS drug approaches.
CNS disorders such as depression, Parkinson’s disease, and Alzheimer’s disease are increasingly recognized as conditions driven by chronic neuroinflammation rather than purely neurotransmitter imbalance. Persistent activation of the NLRP3 inflammasome promotes IL-1β release, microglial activation, synaptic dysfunction, and progressive CNS pathology, limiting the efficacy of symptom-focused therapies such as SSRIs.
This technology provides a heterocyclic compound library based on oxazole and oxadiazole scaffolds, designed for systematic modulation of NLRP3 inflammasome signaling. Modular synthetic routes enable late-stage functional diversification, allowing structure–activity relationship expansion across CNS-relevant chemical space. Multiple KB-series compounds demonstrate dose-dependent suppression of IL-1β release in LPS/ATP-induced inflammasome models, with consistent class-level activity.
In inflammatory depression models, these compounds reduce LPS-induced immobility and attenuate inflammation-driven depressive behaviors, supporting a mechanism distinct from monoaminergic antidepressants. The platform supports CNS subtype–driven efficacy validation, translational biomarker development, and expansion toward preclinical programs. Commercialization opportunities include IP licensing and collaborative R&D with pharmaceutical and biotech partners focused on disease-modifying CNS therapeutics.
IBU Inc. is a technology commercialization and consulting firm supporting licensing, co-development, and venture creation based on deep-tech and research-originated technologies.
The company operates as a technology transfer partner, startup studio, and accelerator, working with universities, research institutes, and industry players.
IBU Inc. connects technology owners with corporate partners and investors by structuring collaboration models, commercialization strategies, and market-oriented pathways.
Create your free account to connect with Taeho Kim and thousands of other innovative organizations and professionals worldwide
Send a request for information
to Taeho
Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.
Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support
